Clinical Trial Update: Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASP-1929 photoimmunotherapy in combination with cemiplimab for refractory, inoperable, and metastatic non-small cell lung cancer; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP-1929
• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING